Türeci Ö - Search Results

1

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. Mulligan MJ, et al. Among authors: tureci o. Nature. 2020 Oct;586(7830):589-593. doi: 10.1038/s41586-020-2639-4. Epub 2020 Aug 12. Nature. 2020. PMID: 32785213 Clinical Trial.

2

Identification of tumor-associated autoantigens with SEREX.

Türeci O, Usener D, Schneider S, Sahin U. Türeci O, et al. Methods Mol Med. 2005;109:137-54. doi: 10.1385/1-59259-862-5:137. Methods Mol Med. 2005. PMID: 15585919

3

The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes.

Koslowski M, Sahin U, Huber C, Türeci O. Koslowski M, et al. Among authors: tureci o. Hum Mol Genet. 2006 Aug 1;15(15):2392-9. doi: 10.1093/hmg/ddl163. Epub 2006 Jun 29. Hum Mol Genet. 2006. PMID: 16809397

4

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U. Kreiter S, et al. Among authors: tureci o. Cancer Res. 2010 Nov 15;70(22):9031-40. doi: 10.1158/0008-5472.CAN-10-0699. Epub 2010 Nov 2. Cancer Res. 2010. PMID: 21045153

5

Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics.

Kuhn AN, Diken M, Kreiter S, Vallazza B, Türeci Ö, Sahin U. Kuhn AN, et al. Among authors: tureci o. RNA Biol. 2011 Jan-Feb;8(1):35-43. doi: 10.4161/rna.8.1.13767. Epub 2011 Jan 1. RNA Biol. 2011. PMID: 21289486

6

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: tureci o. Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Curr Opin Immunol. 2011. PMID: 21497074 Review.

7

FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.

Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, Koslowski M, Huber C, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: tureci o. Cancer Res. 2011 Oct 1;71(19):6132-42. doi: 10.1158/0008-5472.CAN-11-0291. Epub 2011 Aug 4. Cancer Res. 2011. PMID: 21816907

8

Targeting the tumor mutanome for personalized vaccination therapy.

Kreiter S, Castle JC, Türeci O, Sahin U. Kreiter S, et al. Among authors: tureci o. Oncoimmunology. 2012 Aug 1;1(5):768-769. doi: 10.4161/onci.19727. Oncoimmunology. 2012. PMID: 22934277 Free PMC article.

9

Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.

Diken M, Kreiter S, Selmi A, Türeci O, Sahin U. Diken M, et al. Among authors: tureci o. Methods Mol Biol. 2013;969:235-46. doi: 10.1007/978-1-62703-260-5_15. Methods Mol Biol. 2013. PMID: 23296938 Review.

10

Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.

Wöll S, Schlitter AM, Dhaene K, Roller M, Esposito I, Sahin U, Türeci Ö. Wöll S, et al. Among authors: tureci o. Int J Cancer. 2014 Feb 1;134(3):731-9. doi: 10.1002/ijc.28400. Epub 2013 Sep 16. Int J Cancer. 2014. PMID: 23900716 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

190 results

Search Page